Clinical trial
Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for…
NCT00354822 · A.O. Ospedale Papa Giovanni XXIII, Other · Terminated
Key facts
| NCT number | NCT00354822 |
|---|---|
| Title | Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. |
| Official title | Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas. |
| Acronym | Z0105 |
| Lead sponsor | A.O. Ospedale Papa Giovanni XXIII, Other |
| Collaborators | Regional Hospital of Bolzano |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Zevalin |
| Enrollment | 25 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jul 20, 2006 |
| Last update posted | Sep 18, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: